Rezdiffra (Resmetirom) for NAFLD: Off-Label Use, Evidence, and Monitoring

What Rezdiffra Is Approved For (and What It Is Not)

The FDA granted accelerated approval to resmetirom (Rezdiffra) in March 2024, making it the first drug specifically approved for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) in adults with moderate to advanced hepatic fibrosis (stages F2-F3) [1]. This approval was based on a surrogate endpoint (MASH resolution without worsening fibrosis), not a clinical outcomes measure like reduced progression to cirrhosis [2].

NAFLD (now termed MASLD under the 2023 multi-society Delphi consensus) encompasses a spectrum from simple steatosis through steatohepatitis to fibrosis and cirrhosis [3]. Simple steatosis without inflammation or fibrosis affects roughly 25% of the global adult population [4]. Rezdiffra's label explicitly covers MASH with F2-F3 fibrosis. Prescribing it for NAFLD/MASLD without histologically confirmed steatohepatitis and moderate fibrosis falls outside the approved indication. That distinction matters for insurance coverage, informed consent, and the risk-benefit calculation since patients with simple steatosis face a more benign natural history than those with fibrotic MASH [5].

How Resmetirom Works in the Liver

Resmetirom selectively activates thyroid hormone receptor beta (THR-beta), the dominant thyroid receptor isoform in hepatocytes [6]. THR-beta activation increases hepatic fatty acid beta-oxidation, reduces de novo lipogenesis, and lowers circulating LDL cholesterol and triglycerides. The drug was designed for liver selectivity: it concentrates in hepatic tissue and has minimal activity on THR-alpha in the heart and bone, which reduces the risk of tachycardia and bone mineral density loss seen with non-selective thyroid hormone analogs [7].

In the phase III MAESTRO-NASH trial (N=966), patients on resmetirom 100 mg daily achieved a mean 45% relative reduction in liver fat content by MRI-proton density fat fraction (MRI-PDFF) at 52 weeks, versus approximately 10% in the placebo arm [8]. These hepatic fat reductions were accompanied by significant decreases in LDL-C (approximately 16%) and triglycerides (approximately 20%), both of which carry relevance for the cardiovascular comorbidity burden in MASLD populations [9].

The selectivity for THR-beta over THR-alpha is roughly 28-fold based on in vitro binding assays [6]. This selectivity profile is what separates resmetirom from older thyroid hormone analogs like eprotirome, which was abandoned in phase III due to cartilage toxicity in preclinical models [10].

The MAESTRO-NASH Trial: What It Showed (and Did Not Show)

MAESTRO-NASH was a 54-week, randomized, double-blind, placebo-controlled trial that enrolled adults with biopsy-confirmed MASH and fibrosis stages F1B through F3 [8]. The two co-primary endpoints at week 52 were MASH resolution with no worsening of fibrosis and a ≥1 stage improvement in fibrosis with no worsening of the NAFLD Activity Score.

For MASH resolution, 25.9% of the 80 mg group and 29.9% of the 100 mg group met the endpoint, compared with 9.7% on placebo (P<0.001 for both doses) [8]. For fibrosis improvement, 24.2% (80 mg) and 25.9% (100 mg) achieved at least one stage of fibrosis reduction versus 14.2% on placebo [8]. The FDA based its accelerated approval on the MASH resolution endpoint.

A few points demand attention. The trial enrolled patients with F1B-F3 fibrosis, but the FDA approved only for F2-F3. Patients with F1A or F0 fibrosis (the population most relevant to a "NAFLD without significant fibrosis" question) were excluded entirely [2]. No long-term clinical outcome data (liver transplant, hepatic decompensation, mortality) are available yet. The confirmatory MAESTRO-OUTCOMES trial is ongoing, with results expected by 2028 [11].

The absence of efficacy data in early-stage MASLD is the central gap. Liver fat reduction was strong across fibrosis stages in MAESTRO-NASH, which provides biological plausibility for benefit in earlier disease, but plausibility does not equal evidence [8].

Evidence for Off-Label Use in NAFLD Without Fibrosis

No phase III trial has studied resmetirom exclusively in patients with NAFLD/MASLD who lack moderate or advanced fibrosis. The phase II trial (N=125) published in The Lancet in 2019 did include some patients with lower fibrosis stages. In that study, resmetirom 80 mg daily reduced relative hepatic fat by 32.9% versus 10.4% with placebo at 36 weeks (P<0.001 by MRI-PDFF) [12]. Approximately 30% of participants in that phase II had F0-F1 fibrosis, and subgroup analyses suggested comparable liver fat reduction across fibrosis stages, although these subgroups were not powered for definitive conclusions [12].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASLD recommends resmetirom only for patients with biopsy-proven MASH and F2-F3 fibrosis, consistent with the FDA label [13]. The European Association for the Study of the Liver (EASL) has not issued a formal recommendation for resmetirom in MASLD without significant fibrosis [14]. The Endocrine Society's 2024 clinical practice guideline on MASLD management acknowledges resmetirom's hepatic fat reduction but limits its endorsement to the approved population [15].

Using GRADE terminology, the evidence for resmetirom in NAFLD without moderate fibrosis is low quality: biologically plausible, supported by subgroup data from a small phase II, but lacking a dedicated confirmatory trial.

Dr. Rohit Loomba, principal investigator of the MAESTRO-NASH trial, has stated: "The liver fat reduction we see with resmetirom is consistent across fibrosis stages, but we need prospective data in earlier-stage disease before we can recommend it broadly for MASLD without fibrosis" [8].

Monitoring Requirements for Off-Label Prescribing

Regardless of whether resmetirom is used on-label or off, the FDA prescribing information mandates specific monitoring [2]. Off-label use arguably demands even closer surveillance because the risk-benefit ratio is less well characterized. The AASLD guidance reinforces these monitoring protocols for any patient receiving resmetirom [13].

Thyroid Function

Resmetirom suppresses TSH through its THR-beta activity. Median TSH declined by approximately 40% in MAESTRO-NASH but generally remained within the normal range [8]. The prescribing information requires TSH and free T4 at baseline, at 4 weeks, at 8 weeks, and every 6 to 12 months thereafter [2]. TSH below the lower limit of normal or clinical signs of hyperthyroidism (resting tachycardia, tremor, weight loss) should prompt dose reduction or discontinuation. Patients already receiving levothyroxine may need dose adjustment. Co-prescribing resmetirom with amiodarone or lithium has not been studied and warrants additional caution [2].

Liver Enzymes

Transaminase elevations (ALT, AST) occurred in approximately 4-5% of resmetirom-treated patients in MAESTRO-NASH [8]. The label recommends hepatic function tests at baseline, monthly for the first 6 months, then every 3 months [2]. ALT or AST exceeding 5 times the upper limit of normal requires discontinuation. Given that NAFLD patients often have baseline transaminase elevations, establishing a reliable pre-treatment baseline is necessary. The AASLD recommends using the patient's most stable ALT over the preceding 3 months as the reference value [13].

Gallbladder Events

Gallbladder-related adverse events (cholelithiasis, cholecystitis, biliary colic) occurred in 3.7% of the 100 mg group versus 1.5% on placebo in MAESTRO-NASH [8]. THR-beta agonism increases bile acid flux, which may promote gallstone formation [16]. The FDA label advises monitoring for signs and symptoms of gallbladder disease. Patients with a history of cholelithiasis or cholecystectomy should be counseled. Routine gallbladder ultrasound is not mandated by the label but some hepatologists recommend baseline imaging, especially for off-label prescribing where the benefit threshold is higher [2].

Lipid Panel

Resmetirom reliably reduces LDL-C (approximately 14-16%) and triglycerides (approximately 18-20%) [9]. While these changes are generally favorable, patients on existing lipid-lowering therapy may require dose adjustments. Fasting lipid panels at baseline, 12 weeks, and every 6 months are consistent with the trial monitoring schedule [8]. A paradoxical increase in LDL-C should prompt evaluation for non-adherence or drug interaction rather than being attributed to the medication [17].

Drug Interactions

Resmetirom is metabolized by CYP2C8 and CYP3A4 [2]. Strong CYP2C8 inhibitors (gemfibrozil) are contraindicated because they increase resmetirom exposure approximately 2-fold [2]. Moderate CYP3A4 inhibitors require caution. Bile acid sequestrants may reduce resmetirom absorption, so the label recommends dosing resmetirom at least 4 hours before or after bile acid sequestrants [2]. Statin co-administration does not require adjustment based on pharmacokinetic data from the clinical program [9].

Practical Considerations: Cost, Access, and Informed Consent

Rezdiffra carries a wholesale acquisition cost exceeding $40,000 annually [18]. Most commercial payers and Medicare Part D plans have applied prior authorization criteria that mirror the FDA label (biopsy-confirmed MASH with F2-F3 fibrosis). Off-label prescriptions are routinely denied at the prior authorization stage. Some specialty pharmacies will process manufacturer copay assistance, but this typically requires an ICD-10 code consistent with the approved indication (K75.81 for MASH) [18].

Clinicians considering off-label resmetirom for a NAFLD patient should document the clinical rationale in the medical record, obtain explicit informed consent acknowledging the off-label status, and ensure the patient understands that insurance denial is likely. The American Medical Association's Code of Ethics affirms physicians' right to prescribe off-label when supported by clinical judgment, but places the burden of disclosure squarely on the prescriber [19].

Who Might Be Considered for Off-Label Use

Not every NAFLD patient is a reasonable candidate. A framework for clinical decision-making might include patients who meet all of the following: MRI-PDFF confirming steatosis above 10%, elevated ALT suggesting steatohepatitis, one or more metabolic risk factors (type 2 diabetes, BMI ≥30, dyslipidemia), failure or intolerance of first-line lifestyle intervention sustained for at least 6 months, and fibrosis stage F1 on non-invasive assessment (FIB-4, vibration-controlled transient elastography) [20]. Patients with F0 steatosis alone, normal aminotransferases, and no metabolic comorbidities face a low probability of liver-related morbidity and are unlikely to derive net benefit from a drug with gallbladder risk, TSH suppression, and $40,000 annual cost [5].

The AASLD 2023 practice guidance recommends structured lifestyle intervention (7-10% body weight loss) as first-line therapy for all MASLD stages, with pharmacotherapy reserved for patients with biopsy-confirmed MASH and at least F2 fibrosis [13]. Pioglitazone and vitamin E remain alternative pharmacologic options for MASH without advanced fibrosis, with longer safety track records [21]. The PIVENS trial (N=247) demonstrated that vitamin E 800 IU daily achieved NASH resolution in 36% vs. 21% with placebo at 96 weeks in non-diabetic, non-cirrhotic patients [21].

Emerging Data and the Road Ahead

The MAESTRO-NAFLD-1 trial (NCT04197479), a phase III study of resmetirom in patients with presumed NAFLD (without biopsy requirement), has completed enrollment and is expected to report topline data in 2026 [11]. This trial uses non-invasive endpoints (MRI-PDFF, FibroScan) rather than biopsy-based histology. If positive, it could broaden the evidence base for resmetirom in earlier-stage liver disease and potentially support a supplemental New Drug Application for label expansion [11].

The Endocrine Society has identified THR-beta agonism as a priority research area given the overlap between metabolic dysfunction and liver disease [15]. Combination strategies pairing resmetirom with GLP-1 receptor agonists (semaglutide, tirzepatide) are under investigation in early-phase trials, based on the rationale that hepatic THR-beta activation and GLP-1-mediated weight loss may produce additive or synergistic liver fat clearance [22].

Until MAESTRO-NAFLD-1 reports, the evidence level for resmetirom in NAFLD without significant fibrosis remains low, and off-label prescribing should be approached as a shared clinical decision with full monitoring in place.

Clinicians prescribing resmetirom off-label for NAFLD should check TSH and free T4 at weeks 4 and 8, obtain hepatic function panels monthly for 6 months, screen for gallbladder symptoms at each visit, and reassess MRI-PDFF at 6 months to confirm a measurable fat reduction of at least 30% relative to baseline before continuing therapy [2].